Novocure Launches INNOVATE 3 Trial Of Ovarian Cancer Therapy

 
• By Reed Miller

INNOVATE 3 is a phase 3 pivotal trial testing the efficacy of Novocure's Tumor Treating Fields therapy combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

RXXf1 clw
Novocure's Tumor Treating Fields therapy for ovarian cancer. • Source: Novocure Ltd.

More from R&D

More from Business